{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,30]],"date-time":"2026-01-30T09:56:38Z","timestamp":1769766998428,"version":"3.49.0"},"reference-count":23,"publisher":"Public Library of Science (PLoS)","issue":"1","license":[{"start":{"date-parts":[[2026,1,29]],"date-time":"2026-01-29T00:00:00Z","timestamp":1769644800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"The Clinical Evidence-Based Research Special Project for the Construction of High-Level Traditional Chinese Medicine Hospitals of Wangjing Hospital, China Academy of Chinese Medical Sciences","award":["WJYY-XZKT-2023-14"],"award-info":[{"award-number":["WJYY-XZKT-2023-14"]}]}],"content-domain":{"domain":["www.plosone.org"],"crossmark-restriction":false},"short-container-title":["PLoS One"],"abstract":"\n Background<\/jats:title>\n Dwarfism, a condition characterized by short stature, has been the focus of therapeutic advancements with the emergence of novel peptide drugs. Vosoritide, indicated for certain types of dwarfism, has shown therapeutic potential in clinical trials. However, a comprehensive safety profile is essential for its clinical application. The current literature lacks a detailed assessment of vosoritide\u2019s safety, indicating a significant gap that this study aims to address.<\/jats:p>\n <\/jats:sec>\n \n Methods<\/jats:title>\n We conducted a retrospective pharmacovigilance study by analyzing the FDA Adverse Event Reporting System (FAERS) database to evaluate adverse events (AEs) associated with vosoritide monotherapy. The study employed a case\/non-case methodology and applied signal detection algorithms, including the Reporting Odds Ratio (ROR), Proportional Reporting Ratio (PRR), Bayesian Confidence Propagation Neural Network (BCPNN), and Multi-Item Gamma Poisson Shrinker (MGPS), to identify AE signals related to vosoritide use.<\/jats:p>\n <\/jats:sec>\n \n Results<\/jats:title>\n The study included 9319269 reports from the FAERS database, covering the period from 2022 to 2023, with 274 reports specifically citing vosoritide. A significant number of AEs were identified, with a notable incidence in the pediatric population. The most frequently reported AEs were related to endocrine disorders, including altered growth hormone levels and glucose homeostasis issues. Other affected system organ classes (SOCs) were infections and infestations, as well as skin and subcutaneous tissue disorders. Specific preferred terms (PTs) associated with vosoritide included \u201cgrowth deceleration,\u201d \u201cglycemic dysregulation,\u201d and \u201clocal injection site reactions.\u201d<\/jats:p>\n <\/jats:sec>\n \n Conclusion<\/jats:title>\n The findings from this study underscore the importance of close monitoring of vosoritide treatment, particularly in pediatric patients. The identification of both expected and unexpected AEs highlights the necessity for ongoing pharmacovigilance and further research to fully understand the safety profile of vosoritide in clinical practice. This study contributes to the broader field by emphasizing the critical need for patient safety considerations in the development of new therapeutic agents.<\/jats:p>\n <\/jats:sec>","DOI":"10.1371\/journal.pone.0341323","type":"journal-article","created":{"date-parts":[[2026,1,29]],"date-time":"2026-01-29T18:22:41Z","timestamp":1769710961000},"page":"e0341323","update-policy":"https:\/\/doi.org\/10.1371\/journal.pone.corrections_policy","source":"Crossref","is-referenced-by-count":0,"title":["Exploring adverse events associated with vosoritide monotherapy: Insights from the FDA Adverse Event Reporting System"],"prefix":"10.1371","volume":"21","author":[{"given":"Xiaomin","family":"Li","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiangli","family":"Luo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fei","family":"Liu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0009-0002-6607-7214","authenticated-orcid":true,"given":"Chaolu","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiaoming","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Huaixi","family":"Yu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"340","published-online":{"date-parts":[[2026,1,29]]},"reference":[{"key":"pone.0341323.ref001","article-title":"Objectives and design of the Acorn Study: a non-interventional study evaluating long-term safety in achondroplasia patients treated with vosoritide","author":"JM Pimenta","year":"2023","journal-title":"Medical.biomarin.com"},{"issue":"5","key":"pone.0341323.ref002","article-title":"Two cases of cardiovascular adverse events following subcutaneous vosoritide injection in early infancy","volume":"16","author":"A Nishioka","year":"2024","journal-title":"Cureus"},{"issue":"3","key":"pone.0341323.ref003","first-page":"96","article-title":"The treatment of growth disorders in childhood and adolescence","volume":"121","author":"J Woelfle","year":"2024","journal-title":"Dtsch Arztebl Int"},{"issue":"11","key":"pone.0341323.ref004","doi-asserted-by":"crossref","first-page":"1127","DOI":"10.1001\/jamapediatrics.2023.3575","article-title":"The role of genetic testing for short stature now and in the future","volume":"177","author":"MH Wojcik","year":"2023","journal-title":"JAMA Pediatr"},{"key":"pone.0341323.ref005","article-title":"Vosoritide treatment for children with hypochondroplasia: a phase 2 trial.","author":"A Dauber","year":"2024","journal-title":"Lancet"},{"issue":"8","key":"pone.0341323.ref006","doi-asserted-by":"crossref","DOI":"10.1002\/ajmg.a.63612","article-title":"Clinical outcomes and medical management of achondroplasia in Japanese children: a retrospective medical record review of clinical data","volume":"194","author":"H Saitou","year":"2024","journal-title":"Am J Med Genet A"},{"issue":"3","key":"pone.0341323.ref007","first-page":"207","article-title":"Vosoritide: a comprehensive review of the first targeted therapy for achondroplasia","volume":"24","author":"JR Rochester","year":"2023","journal-title":"Expert Opin Pharmacother"},{"issue":"10252","key":"pone.0341323.ref008","doi-asserted-by":"crossref","first-page":"684","DOI":"10.1016\/S0140-6736(20)31541-5","article-title":"Once-daily, subcutaneous vosoritide therapy in children with achondroplasia: a randomised, double-blind, phase 3, placebo-controlled, multicentre trial","volume":"396","author":"R Savarirayan","year":"2020","journal-title":"Lancet"},{"issue":"1","key":"pone.0341323.ref009","article-title":"Advances in the management of achondroplasia with vosoritide therapy","volume":"107","author":"E Rosenberg","year":"2022","journal-title":"J Clin Endocrinol Metab"},{"key":"pone.0341323.ref010","first-page":"88","article-title":"The biology and treatment of achondroplasia: from mouse models to future therapeutic strategies","volume":"127","author":"WA Horton","year":"2019","journal-title":"Bone"},{"issue":"1","key":"pone.0341323.ref011","first-page":"56","article-title":"Achondroplasia: clinical features and complications","volume":"15","author":"RM Pauli","year":"2020","journal-title":"Orphanet J Rare Dis"},{"issue":"1","key":"pone.0341323.ref012","first-page":"5","article-title":"Genetic testing and pharmacotherapy in children with short stature: focusing on achondroplasia","volume":"64","author":"T Himeno","year":"2022","journal-title":"Pediatrics Int"},{"issue":"10","key":"pone.0341323.ref013","first-page":"614","article-title":"Targeted therapies for skeletal dysplasias: the case of vosoritide in achondroplasia","volume":"17","author":"EB Hunziker","year":"2021","journal-title":"Nat Rev Rheumatol"},{"issue":"6","key":"pone.0341323.ref014","doi-asserted-by":"crossref","first-page":"487","DOI":"10.7150\/ijms.8.487","article-title":"Adverse event profiles of platinum agents: data mining of the public version of the FDA adverse event reporting system, AERS, and reproducibility of clinical observations","volume":"8","author":"T Sakaeda","year":"2011","journal-title":"Int J Med Sci"},{"issue":"6","key":"pone.0341323.ref015","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1002\/pds.1742","article-title":"Quantitative signal detection using spontaneous ADR reporting","volume":"18","author":"A Bate","year":"2009","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"pone.0341323.ref016","article-title":"Pediatric pharmacovigilance: challenges, opportunities, and future directions","volume":"59","author":"CY Lee","year":"2019","journal-title":"J Clin Pharmacol"},{"key":"pone.0341323.ref017","first-page":"70","article-title":"Endocrine adverse effects of targeted therapies in oncology","volume":"11","author":"F Bellet","year":"2020","journal-title":"Front Endocrinol"},{"issue":"9237","key":"pone.0341323.ref018","doi-asserted-by":"crossref","first-page":"1255","DOI":"10.1016\/S0140-6736(00)02799-9","article-title":"Adverse drug reactions: definitions, diagnosis, and management","volume":"356","author":"IR Edwards","year":"2000","journal-title":"Lancet"},{"issue":"2","key":"pone.0341323.ref019","first-page":"364","article-title":"Geographical variation in adverse drug reaction reporting in Europe: An analysis of Northern, Southern, and Eastern countries","volume":"108","author":"ST de Vries","year":"2020","journal-title":"Clin Pharmacol Ther"},{"issue":"3","key":"pone.0341323.ref020","first-page":"315","article-title":"Pharmacovigilance for evaluating adverse drug reactions: value, organization, and methods","volume":"5","author":"JL Montastruc","year":"2006","journal-title":"Exp Opin Drug Saf"},{"issue":"10","key":"pone.0341323.ref021","doi-asserted-by":"crossref","first-page":"851","DOI":"10.2165\/00002018-200528100-00003","article-title":"Clarification of terminology in drug safety","volume":"28","author":"JK Aronson","year":"2005","journal-title":"Drug Saf"},{"issue":"7456","key":"pone.0341323.ref022","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1136\/bmj.329.7456.44","article-title":"Detection, verification, and quantification of adverse drug reactions","volume":"329","author":"BHC Stricker","year":"2004","journal-title":"Br Med J"},{"issue":"5","key":"pone.0341323.ref023","first-page":"407","article-title":"Systematic review on the prevalence, frequency, and comparative value of adverse event data in the WHO VigiBase as compared with published reports","volume":"34","author":"S Golder","year":"2011","journal-title":"Drug Saf"}],"container-title":["PLOS One"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0341323","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,29]],"date-time":"2026-01-29T18:22:45Z","timestamp":1769710965000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0341323"}},"subtitle":[],"editor":[{"given":"Eric HY","family":"Lau","sequence":"first","affiliation":[],"role":[{"role":"editor","vocabulary":"crossref"}]}],"short-title":[],"issued":{"date-parts":[[2026,1,29]]},"references-count":23,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,1,29]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pone.0341323","relation":{},"ISSN":["1932-6203"],"issn-type":[{"value":"1932-6203","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1,29]]}}}